Advertisement Pharmaceutical Business review - Page 5 of 5225 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 21, 2024

Laekna partners with Lilly to develop obesity therapy

Laekna has entered into a clinical partnership with Eli Lilly to advance the development of LAE102, a new ActRIIA monoclonal antibody for treating obesity.

The partnership is set to concentrate on clinically assessing and developing the monoclonal antibody for treating obesity. Credit: Michał Parzuchowski on Unsplash.